Consolidated Statements of Operations - USD ($) $ in Thousands |
12 Months Ended | |
|---|---|---|
Dec. 31, 2024 |
Dec. 31, 2023 |
|
| Operating expenses | ||
| Research and development | $ 6,645 | $ 6,131 |
| Research and development - licenses acquired | 0 | 4,230 |
| General and administrative | 4,638 | 4,179 |
| Loss from operations | (11,283) | (14,540) |
| Interest income | (176) | (126) |
| Financing costs – warrant liabilities | 0 | 332 |
| Loss on common stock warrant liabilities | 759 | 0 |
| Change in fair value of warrant liability | (170) | (4,258) |
| Net loss | (11,696) | (10,488) |
| Net loss attributable to non-controlling interest | (44) | (111) |
| Net loss attributable to common stockholders | $ (11,652) | $ (10,377) |
| Net loss per common share attributable to common stockholders, basic and diluted (in dollars per share) | $ (15.79) | $ (73.48) |
| Weighted average number of common shares outstanding, basic and diluted (in shares) | 1,295,207 | 141,222 |
| X | ||||||||||
- Definition Amount of total financing costs associated with the public offering allocated to derivative warrant liabilities. No definition available.
|
| X | ||||||||||
- Definition Amount of loss on warrant liabilities classified as inducement fee. No definition available.
|
| X | ||||||||||
- Definition Amount of research and development cost incurred for licenses acquired. No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|